Global /South Korea /Healthcare /Drug Manufacturers - General /003220
chevron_leftBack
Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd.

003220
KRX: 003220 Delayed
10,720KRW -0.8%
7.10 USD
As of 18 June 2026, Daewon Pharmaceutical Co., Ltd. has a market cap of $153.5M USD, ranking #22766 globally and #982 in South Korea. It ranks #2045 in the Healthcare sector, and #736 in the Drug Manufacturers - General industry.
Global Rank
22766
Country Rank
982
Sector Rank
2045
Industry Rank
736
Key Stats
Market Cap
$153.5MUSD
231.7B KRW
Enterprise Value
$242.42MUSD
365.91B KRW
Revenue (TTM)
$401.11MUSD
605.43B KRW
EBITDA (TTM)
$18.04MUSD
27.23B KRW
Net Income (TTM)
-$914.06KUSD
-1.38B KRW
EBITDA Margin
4.5%
Profit Margin
-0.2%
Forward PE
16.2
PS Ratio
0.4
PB Ratio
0.8
EV/EBITDA
13.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Seung-Ryel Baek open_in_new
Employees
1,283
Founded
1958
Website
daewonpharm.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-0.8% 1.5% 2.8% -6.9% -18% -21%

News

Loading...

Markets

Exchange Ticker Price
Korea Exchange
MIC: XKRX
PRIMARY
003220
대원제약(주)
ISIN: KR7003220001
Shares Out.:
21.433M1 Shares Float: 12.4M2
TV:
SA:
YF:
GF:
BA:
MS:
10,720 KRW
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Daewon Pharmaceutical Co., Ltd.

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company’s principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 40 countries primarily in Asia, Central and South America, the Middle East, CIS, and Africa. The company was founded in 1958 and is headquartered in Seoul, South Korea.

Similar Companies

Industry: Drug Manufacturers - General (South Korea)
Name
Market Cap diff.
PE
$9.22B
13.91T KRW
6K%
-
$6.83B
10.3T KRW
4K%
1958.1
$5.28B
7.97T KRW
3K%
29.9
298380
$5.0B
7.55T KRW
3K%
-
000100
$4.58B
6.92T KRW
3K%
35.9
$4.48B
6.76T KRW
3K%
-
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
496K%
38.1
JNJ
$547.28B
356K%
26.4
ABBV
$360.63B
235K%
97.4
$323.08B
256.25B CHF
210K%
19.9
AZN
$289.5B
215.59B GBP
188K%
27.6
NOVN
$275.99B
218.9B CHF
180K%
20.5
chevron_leftBack